Valeant, Salix Pharma file paperwork with US antitrust regulator
MLex Summary: Specialty pharmaceutical company Valeant Pharmaceuticals International and Salix Pharmaceuticals filed paperwork seeking US antitrust approval for their planned $158-per-share deal on Feb. 27 and March 2, respectively, according to a filing with...To view the full article, register now.
Already a subscriber? Click here to view full article